← FDA DRUG APPROVALS

FDA ANDA · ANDA073393

TOLMETIN SODIUM

Sponsor: RISING

APPLICATION
ANDA073393
TYPE
ANDA
ORIGINAL APPROVAL
1993-05-27
LATEST ACTION
2024-11-21
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Prescription

Products

TOLMETIN SODIUMPrescription
TOLMETIN SODIUM EQ 400MG BASE · CAPSULE · ORAL

Approval history

2024-11-21Labeling · Supplement 14 · standardAP
2021-04-28Labeling · Supplement 11 · standardAP
2016-05-09Labeling · Supplement 8 · standardAP
2008-07-31Labeling · Supplement 3AP
2006-08-08Labeling · Supplement 2AP
1998-02-05Manufacturing (CMC) · Supplement 1AP
1993-05-27OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →